Cell growth attenuation in esophageal cancer and apoptosis promotion in ovarian and breast cancers is enabled by irreversible GCL inhibitor-buthionine sulfoximine (BSO) via reduction in GSH production (181). This evidence concerns the gene GCLC and breast carcinoma.